At present, although there are Zongguo products everywhere abroad, only Zongguo's domestic medicine is almost impossible to buy abroad.

For China's pharmaceutical industry, drug research and development has always been a tangled topic.

Although in recent years, driven by policies and markets, the concentration of China's pharmaceutical industry has increased, and the level of drug research and development has begun to improve to a certain extent, the gap between China's pharmaceutical industry and countries with mature R&D systems is still very large.

At present, the number of innovative drugs with independent intellectual property rights in China is very small, and there is no market for innovative drugs in foreign countries, and there are very few domestic pharmaceutical companies that really go abroad, and more are just trying to survive in the domestic market.

However, the innovative drugs developed by foreign pharmaceutical companies are very popular in the domestic market, which is a very regrettable and sad thing.

However, now Changhua Pharmaceutical has changed this situation, not only pushing the drug to the foreign market for sales, but also the sales volume is very high, basically in short supply, and the agent has also come to urge the goods three times and twice.

As a member of Changhua Pharmaceutical, Li Changhua will naturally feel full of pride and pride in this.

"Agents also want us to increase our supply so that they can get more drugs to sell." Li Changhua continued.

This is also very normal, the agent sees that the sales of these drugs are so good, of course, they hope to get more volume, so that they can make more money.

However, with the current output of Changhua Pharmaceutical, it is impossible to increase the supply.

Unless Changhua Pharmaceutical's output can be increased, there is this possibility.

But so far. Changhua Pharmaceutical has no plans to provide production. And even Changhua Pharmaceutical will have a plan to increase production. It will also not increase the supply volume of dealers.

"It is impossible to increase the supply volume, and even if the production is increased, it is the first thing to increase the number of agents." Su Zhe said.

In Su Zhe's plan, even if the output is increased, it is to find another agent, and first develop the market of other countries, rather than increasing the supply of current agents.

Because now the volume of goods obtained by these agents can barely ensure the demand of their countries.

And Changhua Pharmaceutical wants to provide an international impact. Rather than confined the market to a few countries, we should try to develop other countries and sell drugs to as many countries as possible.

Therefore, Su Zhe does not plan to increase the supply to the current agents, even if the output of Changhua Pharmaceutical increases in the future, he will only look for agents in other countries and hand over the newly increased output to agents in other countries for sale.

Li Changhua and Liu Xiong both nodded, they also knew Changhua Pharmaceutical's current strategic goals, so they said to Su Zhe. No objections were raised.

However, Su Zhe also thought of the current production pressure in the factory. It's getting bigger.

Even after the acquisition of Guanzhou Xinjing Pharmaceutical, in the face of the rapid increase in production plan, with the current production capacity of Changhua Pharmaceutical, it gradually began to be a little unable to cope.

However, before that, Li Changhua and his team deployed a series of plans, such as increasing production lines, and expanding the pharmaceutical factory and the new branch of Guanzhou Xinjing Pharmaceutical, which were all preparations for increasing production capacity.

It is divided into several phases of the plan, and once all are implemented, the production capacity of Changhua Pharmaceutical can be more than doubled, or even increased by several times.

After all, whether it is Changhua Pharmaceutical Factory or Guanzhou Xinjing Pharmaceutical, there are many vacant land that has not yet been utilized.

If these vacant lands are utilized, new branches are built, and new production lines are installed, the production capacity of Changhua Pharmaceutical will definitely be greatly improved.

However, this is not something that can be completed in a short time and a half, and it will take a lot of time to achieve.

In a short period of time, Changhua Pharmaceutical's output plan has been increased several times in a row.

Although the current production capacity of Changhua Pharmaceutical can still cope with it, if the output is increased again, the production capacity will be close to saturation, and it will be difficult to meet the new output plan.

But the new expansion plan could not be completed so quickly.

This is one of the problems that Changhua Pharmaceutical needs to face in its current development, and improving production capacity is the top priority.

Su Zhe also did not expect that Changhua Pharmaceutical's production capacity would approach the limit so quickly.

Originally, Su Zhe thought that after the acquisition of Guanzhou Xinjing Pharmaceutical, Changhua Pharmaceutical's production capacity would not have to worry about it for a long time.

However, it has not been long since the acquisition, and now Changhua Pharmaceutical needs to face this problem again.

This is something Su Zhe didn't expect, but this is also Changhua Pharmaceutical's output plan, which has been increased too much, so the current production capacity will reach the limit so quickly.

However, this also shows that Changhua Pharmaceutical is developing rapidly, and the drugs launched are very popular in the market, so the production capacity will not keep up, and there is a situation where supply exceeds demand.

In general, this is still a good thing for Changhua Pharmaceutical.

It's just that Su Zhe and the others need to discuss the issue of increasing production capacity now.

It is still the same as before, it is still the old way, accelerating the expansion of Changhua Pharmaceutical's new pharmaceutical factory, and at the same time, it has also begun to look for suitable pharmaceutical factories for acquisition to increase Changhua Pharmaceutical's production capacity.

This is the plan that Su Zhe and Li Changhua came up with after consultation, and they can only do this at present.

In general, it is also a good thing that Changhua Pharmaceutical's output plan can be increased several times in a short period of time, which also indirectly shows that the development of Changhua Pharmaceutical is getting faster and faster, and the demand for it in the market is also getting bigger and bigger.

This is exactly what Su Zhe and the others expect from Changhua Pharmaceutical, and now that they have done this, this is naturally a very happy thing.

The things that should be discussed have now been discussed, and the things that should be explained have been ordered.

Therefore, this is the end of today's meeting.

Although Li Changhua and Liu Xiong didn't know what method Su Zhe used to get the formula of the joint spirit, although they were very curious, they didn't ask.

Everyone has their own secrets and doesn't want people to know, so if Su Zhe doesn't take the initiative to say it, Li Changhua and Liu Xiong won't ask.

Anyway, Su Zhe handed over the formula of Joint Spirit to Changhua Pharmaceutical for development, which is beneficial to everyone.

Therefore, Li Changhua and Liu Xiong both believe that there are some things that do not need to be asked, so as not to destroy their trust in each other.

This is the way Li Changhua and Liu Xiong deal with it, and it is also the attitude towards their collaborators.

In this way, Su Zhe also had a lot of peace of mind, at least he didn't have to find a way to explain the source of the joint spirit. (To be continued......)